HIV-associated neurocognitive disorders are highly prevalent, and physical activity (PA) is a modifiable behaviour that may affect neurocognitive function. Our objective was to determine the association between PA and neurocognitive function and the effect of HIV on this association.
Introduction
HIV-associated neurocognitive disorder (HAND) is a highly prevalent complication of HIV infection currently affecting an estimated 40-50% of individuals with HIV infection [1] . It typically manifests as a decline in memory and concentration [2] . Both direct neurotoxicity of HIV and neurotoxic factors produced by macrophages in response to HIV have been implicated in the pathology of HAND [3] , and the exact mechanism of the cognitive deficits remains only partially understood. As HIVinfected patients live longer with antiretroviral therapy, interventions to decrease the detrimental effects of HIV and aging on cognition are needed, and one potential intervention is physical activity (PA). PA has effects at the molecular level, by increasing neurotrophins and growth factors, at the cellular level, through neurogenesis, synaptic plasticity, and angiogenesis, and at the systems level, by increasing brain volume and blood flow [4] .
Aerobic exercise intervention studies have shown a benefit of aerobic exercise in terms of cognitive measures among HIV-uninfected populations. Controlled trials have shown specific benefits for executive function in a variety of individuals: children and adults with normal cognition [5] [6] [7] [8] , and adults with mild cognitive impairment [9, 10] . The data in HIV-infected populations are limited and have been mixed. In a study of 335 community-dwelling HIV-infected adults, selfreported recent engagement in exercise (exercise vs. no exercise in the past 72 h) was significantly associated with lower rates of global neurocognitive impairment (NCI), which was significant after adjusting for demographic factors, HIV disease characteristics, substance use disorders, past and current depression, mental health status, and physical functioning. In that study, lower rates of impairment in working memory and speed of information processing were significantly associated with more exercise [11] . Similarly, among 100 HIV-infected individuals older than 50 years, higher levels of moderate PA were associated with lower odds of NCI, with the association driven by executive function [12] . One randomized controlled trial of a 6-month supervised exercise programme showed an improvement in the self-reported cognitive function domain of the Medical Outcomes Study HIV Health Survey [13] . In contrast to the beneficial results described above, a 1999 study of 139 asymptomatic HIV-infected men showed only a minimal effect of exercise on neuropsychological functioning [14] . A knowledge gap still exists regarding the level of exercise that is beneficial and whether exercise can overcome the chronic inflammation associated with HIV infection.
Our objective was to determine the association between PA and neurocognitive function and the effect of HIV infection on this association. We had the benefit of an HIV-uninfected control group, which allowed us to compare the effects in our HIV-infected population with effects in a similar group. We hypothesized that PA would be associated with better neurocognitive function among all HIV-infected and HIVuninfected men in the Multicenter AIDS Cohort Study (MACS). Furthermore, we hypothesized that a higher level of PA would be associated with a lower speed of decline of neurocognitive function in both HIV-infected and HIV-uninfected men.
Methods
We undertook two analyses, a cross-sectional analysis and an analysis using longitudinal data, with data from the MACS, which has previously been described [15] . Briefly, the study was initiated in 1984 as a study of men who have sex with men with or at risk for HIV infection conducted at four study sites in Baltimore/ Washington, DC, Chicago, Los Angeles, and Pittsburgh. A total of 7343 men have been enrolled over four time periods (1984-1985, 1987-1990, 2001-2003 and 2010 to present). The study includes brief neurocognitive assessments at each visit (semianually), and a complete neuropsychological battery every 2 years.
Inclusion criteria
This analysis was restricted to the 601 men who completed the International Physical Activity Questionnaire (IPAQ) at visit 53 and/or 54, which took place from April 2010 to March 2011 (these were the only two visits at which PA was measured, and are hereafter referred to as the 'baseline' visits), and had the full neuropsychiatric battery within 180 days of their IPAQ administration. Although the visit numbers for the IPAQ administration were visits 53 and 54 per the visit numbering schema in the MACS, for each participant these visits might not reflect their 53rd or 54th visit, depending on their year of enrolment in the MACS.
Predictor variable
Exercise was measured using the short form of the IPAQ, which accounts for multiple domains of PA, including leisure time, domestic activities, yard work, physical activity at work, and transportation-related activity [16] . The questionnaire captures various activity intensities: walking, moderate intensity, and vigorous intensity.
The volume of PA was computed by weighting each type of activity by its energy requirements defined in metabolic equivalents (METs) to generate a score in units of MET-minutes. The MET total score is computed as the summation of MET-minutes/week for walking, moderate intensity and vigorous intensity activity. Categorical scores (low, moderate and high) are determined by the following criteria. (1) Low: no activity is reported OR some activity is reported but does not meet criteria for moderate or high activity. (2) Moderate: 3 or more days of vigorous activity of at least 20 min per day OR 5 or more days of moderate activity and/or walking of at least 30 min per day OR 5 or more days of any combination of walking, moderate activity or vigorous activity achieving a minimum of at least 600 METs. (3) High: vigorous activity on at least 3 days and accumulating at least 1500 MET-minutes/week OR 7 or more days of any combination of walking, moderate or vigorous activity accumulating at least 3000 MET-minutes/week [16] .
Outcome variables
The brief neurocognitive assessments are the Symbol Digit Modalities Test (SDMT) and the Trail Making Test (TMT) Parts A and B performed every 6 months. The score on the SDMT is the total number of correct answers and the score on the TMT is the amount of time required to complete the task. A comprehensive neuropsychological examination is administered every 2 years and consists of a 40-min conventional and computerized neuropsychological test battery designed to cover a broad range of cognitive domains. As shown in Supporting Information Table S1 , a total of six domain T-scores were derived, including learning and memory (derived from the learning and delayed recall trials of the Rey-Osterrieth Complex Figure Test [17, 18] and Rey Auditory Verbal Learning Test [19] ), processing speed (Stroop colour naming [20] and SDMT [21] ), motor function (grooved pegboard [22] ), executive function (Stroop interference [20] and TMT B [23] ), and sustained attention (California Computerized Assessment Package (CALCAP) [24] ). Tscores for all tests comprising a domain are averaged to obtain a domain T-score.
For all analyses, normative data adjusted for age, education, race, body mass index (BMI) and number of previous test administrations (none, one, two or more) were used to calculate z-scores (SDMT/TMT A/TMT B) and T-scores (domains). The normative data were derived from the HIV-uninfected MACS participants [25] . T-scores were created so that all directions had the same meaning (i.e. a positive value indicates higher performance, and a negative value indicates lower performance).
For the cross-sectional analyses, cognitive impairment for each of the six domains was defined as an adjusted T-score < 40 (domain deficit score > 0.5). Global impairment was defined as the average of the domain deficit scores ≥ 0.5 [11] .
We also performed analyses using available longitudinal data. All available domain scores and results for SDMT, TMT A and TMT B were used to generate a slope over time for each outcome. The median number of visits contributing to the calculation of the individual slope of each domain was three [interquartile range (IQR) [2] [3] , and the median number of visits contributing to the calculation of the individual slopes of SMDT and TMT A/B was 8 (IQR 8-10).
Additional adjusted variables included in the models were smoking status (self-report; current, former and never), alcohol consumption (self-report; categories 0, 1-3, 4-13 and > 13 drinks/week), stimulant use (self-report; defined as use of any form of cocaine or amphetamines in the last 6 months), hepatitis C virus (HCV) status (chronic HCV infection defined as positive HCV RNA), depressive symptoms [defined as Center for Epidemiologic Studies Depression Scale (CES-D) [26] score > 16], diabetes (defined as fasting glucose > 126 mg/dL or haemoglobin A1c > 6.5, or self-reported history with medication use), hypertension [defined as systolic blood pressure (SBP) > 140 mm, diastolic blood pressure (DBP) > 90 mm, or self-reported history with medication use], and BMI. For HIV-infected men only, additional laboratory values included current CD4 cell count (categories ≤ 199, 200-499 and ≥ 500 cells/lL) and detectable current plasma HIV RNA (defined as plasma HIV RNA ≥ 50 copies/mL). Current antiretroviral therapy was assessed by self-report. AIDS history was assessed by self-report.
Statistical analysis
Demographic characteristics were compared across groups using Wilcoxon (for continuously distributed variables) and v 2 (for categorical variables) tests. Associations between PA and cognitive impairment for each domain and global scale in the entire cohort were determined using logistic regression models. The models were also adjusted for HIV infection status, smoking, drinking, stimulant use, depressive symptoms, HCV infection, diabetes and hypertension. We also tested for an HIVinfection-PA interaction to determine if the association between PA and cognitive impairment differed by HIV infection status. When the cohort was restricted to the HIV-infected participants, additional variables included were categorical CD4 count, AIDS status, highly active antiretroviral therapy (HAART) use, and detectable HIV RNA.
For participants who had available longitudinal data with which to compute the slope of test performance over time (SDMT, TMT A and TMT B) and domain change over time (for each of the domains), multivariate linear regression models were used to explore associations of PA with test score changes. Similar covariates were adjusted for in these models as described in the models above examining cross-sectional outcomes only. All statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC, USA). Statistical significance was considered as a P-value < 0.05.
Results
Demographic and clinical characteristics of study participants are shown in Table 1 . Age did not vary significantly across groups. There were more African-American men among the low-exercise group. Additionally, there were more current smokers and more individuals with depression among the low-exercise group. A higher proportion of HIV-infected men were in the low-exercise group compared with the moderate-or high-exercise groups. Diabetes, hypertension, and BMI were not statistically significantly different across groups. Table 2 shows the presence of impairment in the cognitive domains by HIV infection status. More HIVinfected individuals had impairment in the executive function and working memory domains, although the differences were not statistically significant. For TMT A and B, SDMT and each cognitive domain, we show the slope of change over time. The slope of the working memory and motor domains varied by HIV infection status, with steeper declines among the HIV-infected participants.
As shown in Table 3 Baseline high/moderate PA was not associated with decline of any cognitive domain score over time (Table 5 ). There was a trend towards a steeper decline in motor function over time among individuals with HIV infection (b = À0.72; 95% CI À1.64, 0.01), indicating that the mean decline of motor T-score per year in HIVinfected men was 0.72 units faster compared with that in those without HIV infection. To put this in context, the mean (standard deviation) slope of motor function over time for the men with HIV infection was À0.54 (4.66) vs. 0.22 (3.2) for the men without HIV infection.
As described above, we created a slope from available domain scores (T-scores) and from SDMT, TMT A and TMT B (z-scores). These outcomes are separate from the cognitive impairment outcome, and we were unable to determine whether someone reached an impaired stated after starting unimpaired an individual with an unimpaired status at baseline later became impaired. However, we did look at the participants' impairment (based on the global impairment score) at first available visit, at the IPAQ visit, and at the last available visit. Among HIV-infected individuals, 24% were impaired at the initial visit, 29% at the time of the IPAQ visit, and 31% at the last available visit, compared with 19%, 27%, and 26%, at the three visits, respectively, among the HIV-uninfected men.
Discussion
In this analysis of the association between PA and cognition among HIV-uninfected and HIV-infected men in the MACS, high PA was associated with lower odds of impairment in several domains, including learning, memory, and motor function, in cross-sectional analysis. No HIV infection-PA interaction was noted in the analyses including all men. However, when the results for HIVinfected men were examined separately, despite a smaller sample size, the OR for the inverse association between high PA and cognitive impairment was even more pronounced, which may suggest a stronger protective effect of high PA in the HIV-infected men compared with its effect in all men. When examining neurocognitive outcomes over time, we did not see an association between baseline PA and the slope of decline in performance on the tests. However, our ability to examine the PA-neurocognitive domain association over time was limited by not having time-updated PA assessments. Prior studies of the association between PA and neurocognitive function in HIV infection have used various methods to assess PA and neurocognitive outcomes. Our results are consistent with some findings from prior work. For example, a 2013 study by Dufour and colleagues used a PA assessment in which participants reported how much time they had spent exercising in the past 72 h, which was subsequently categorized into any exercise or no exercise. Results for the 335 individuals revealed that individuals who reported exercise had lower global neurocognitive impairment. When the individual domains were examined, individuals who reported exercise were found to have lower impairment in working memory and processing speed. We saw a trend towards an inverse association between PA and global impairment when both HIV-infected and HIV-uninfected men were included in our analytical sample, and a strong inverse association between PA and global impairment when the HIVinfected men were examined separately. The associations we observed in individual domains differed from the results obtained by Dufour and colleagues; however, this could be related to differences in the tests used to assess the domains and/or differences in the way PA was assessed [11] .
Another study involving HIV-infected individuals older than 50 years demonstrated an association between the mean moderate MET-minutes per week of PA (assessed using the IPAQ continuous score) and lower probability of global NCI, with the association driven by preserved executive function [12] . The authors did not find an CI, confidence interval; OR, odds ratio. *Adjusted for smoking, alcohol use, stimulant use, depression, hepatitis C virus infection, and hypertension. **P < 0.05. Table 4 The association* between physical activity (PA) and impairment in cognitive function domains among HIV-infected individuals: crosssectional data (n = 263) CI, confidence interval; HAART, highly active antiretroviral therapy; OR, odds ratio. *Adjusted for smoking, alcohol use, stimulant use, depression, hepatitis C virus infection, and hypertension. **P < 0.05.
association between the categorical IPAQ variables used in our analysis and global NCI. This may have been a consequence of the smaller sample size (n = 100) compared with the Dufour et al.
[11] study and our study or the inclusion of only older individuals. In another study, a randomized controlled trial of a 6-month supervised exercise programme, there was an improvement in the self-reported cognitive function domain of the Medical Outcomes Study HIV Health Survey among the group of HIV-infected individuals assigned to the exercise intervention [13] . The exercise intervention was 60 min of combined aerobic and resistance training twice per week. There was no objective assessment of neurocognitive function in that study, only the survey. We did not see consistent associations between PA and all neurocognitive domains examined. The mechanisms by which PA may impact neurocognitive function in people with HIV infection is probably multilevel with molecular, cellular and systems effects [4] . PA may also improve comorbidities, such as diabetes and hypertension, that contribute to worse neurocognitive function [27] . We may have seen more consistent effects if we had used ongoing exercise assessments and/or had longer follow-up times. Additionally, some domains, particularly motor-related domains, may be more responsive to the effects of PA.
We did not observe an overall effect of baseline PA on subsequent decline in the individual neurocognitive domains. However, we did observe an association between HIV infection status and steeper slope of decline in the motor domain of the neurocognitive battery. Another assessment performed in the MACS was the assessment of gait speed, with the usual gait speed of individuals being recorded at visits between 2007 and 2013 [28] . Our results are consistent with the effect of HIV infection on gait speed observed in that study, whereby men with HIV infection had a more rapid decline in gait speed over time compared with men without HIV infection (decline was 0.025 m/s per year greater in HIV-infected compared with HIV-uninfected men; P < 0.001).
There were inconsistent results regarding the effect of HIV infection status on impairment in our analysis, and prior work in the MACS has similarly revealed conflicting results. Our unadjusted analyses showed no statistically significant differences in the categorical cognitive impairment outcomes by HIV infection status at the time of the IPAQ assessments ( Table 2 , cross-sectional). HIV infection status was inversely associated with motor domain impairment in adjusted analyses (OR 0.66; 95% CI 0.45, 0.98; Table 3 , cross-sectional). However, in adjusted longitudinal analysis, HIV infection was associated with a higher slope of decline in the motor domain (Table 5 , longitudinal). Prior work by Becker et al. examining psychomotor speed and memory [29] did not show an effect of HIV infection status on psychomotor speed and, interestingly, showed an inverse association between having HIV infection and having poor performance on memory assessment. In both the Becker et al. analysis and our analysis, most HIV-infected individuals were on antiretroviral therapy and did not have a history of AIDS, which may explain why no effect of HIV infection was seen. In discussing their results, Becker et al. commented on the association they found between metabolic and cardiovascular comorbidities (chronic kidney disease, diabetes and hypertension) and cognition, and emphasized the importance of aggressive management of those comorbidities among individuals living with HIV. In the current study, we did not examine any biomarkers thought to be improved by exercise, such as inflammatory markers or markers of oxidative stress, that could subsequently affect cognitive function. The exercise effect on biomarkers, and subsequently cognition, could be hypothesized to be the same in people with and without HIV infection; however, this was not examined in our analysis. Strengths of our study include the large sample size, the longitudinal nature of the detailed neuropsychological assessments performed, and the collection of comprehensive mental health and substance use data. Limitations of our study are that our sample included men only and that causality cannot be determined using cross-sectional analysis. Additional limitations include limited data for nonpsychomotor speed tests and a relatively short period of observation for the longitudinal analyses and no repeated measures of PA. There are also potentially limitations to the IPAQ, because it is a self-reported PA measure. Prior work correlating IPAQ with accelerometry data revealed over-reporting by the IPAQ [30] but concluded that the IPAQ is reasonable for screening. Lee et al. [31] performed a review of studies comparing IPAQ to objective PA measures, and their findings showed acceptable correlations between the IPAQ and objective data for walking and vigorous activity. Additionally, our sample included HIV-infected and HIV-uninfected men only, and a relatively healthy population of HIV-infected men (only 10% with a history of AIDS, the vast majority on antiretroviral therapy, and very few with CD4 < 200 cells/lL). These factors limit the generalizability of our results. Finally, the "baseline" visit for this study, when the IPAQ was administered, was not the first time that participants participated in cognitive assessments. The median number of brief neurocognitive assessments prior to baseline was 17 (IQR 13, 28) and the median number of comprehensive neuropsychological examinations performed was 5 (IQR 3, 9) . This relatively high number of previous tests may have decreased our sensitivity to detect impairment at baseline and subsequent change; however, all test scores were adjusted, as described in the Methods section, for multiple administrations.
Conclusions
We demonstrated associations between self-reported rates of PA and specific neurocognitive outcomes among our study sample. As more of the HIV-infected persons were in the lowest PA category, these results suggest that physical activity may be a therapeutic intervention that could improve psychomotor speed performance in HIV-infected persons. Additional research is needed to delineate the exact mechanism by which PA improves cognitive outcomes and the optimal frequency and duration of PA for these benefits.
